Acticor Biotech SAS (ALACT.PA)
- Previous Close
0.2700 - Open
0.2950 - Bid --
- Ask --
- Day's Range
0.2760 - 0.6700 - 52 Week Range
0.2700 - 6.2200 - Volume
1,658,205 - Avg. Volume
58,523 - Market Cap (intraday)
5.271M - Beta (5Y Monthly) -0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.30
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
www.acticor-biotech.comRecent News: ALACT.PA
Performance Overview: ALACT.PA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALACT.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALACT.PA
Valuation Measures
Market Cap
5.27M
Enterprise Value
4.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
14.32
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.27
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-81.35%
Return on Equity (ttm)
-797.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-18.65M
Diluted EPS (ttm)
-1.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
7.96M
Total Debt/Equity (mrq)
2,160.05%
Levered Free Cash Flow (ttm)
-7.84M
Research Analysis: ALACT.PA
Company Insights: ALACT.PA
ALACT.PA does not have Company Insights